Table 1 |
|||
|
Presenting clinical features and prevalence of autoantibodies in rheumatoid factor positive rheumatoid arthritis (RF + RA), RF-negative RA (RF-RA), and nonRA patients |
|||
| RF + RA |
RF - RA |
Non RA |
|
| (n = 70) |
(n = 36) |
(n = 132) |
|
|
|
|||
| Age |
47 ± 12 |
44 ± 14 |
39 ± 13* |
| Female |
44 (63) |
27 (75) |
87 (66) |
| Swollen joint count |
13 ± 9 |
16 ± 10 |
2 ± 3* |
| CRP level |
1.9 ± 1.9 |
1.9 ± 2.1 |
1.6 ± 2.4 |
| Multiple erosions |
12 (17) |
7 (19) |
7 (5)* |
| RF |
70 (100) |
0 |
17 (13) |
| ANA |
25 (36) |
10 (28) |
30 (23) |
| ds-DNA |
0 |
0 |
3(2) |
| Anti-SSA |
5 (7) |
2 (6) |
7 (5) |
| Anti-SSB |
2 (3) |
1 (3) |
2 (2) |
| Anti-RNP |
3 (4) |
0 |
3 (2) |
| Anti-Sm |
0 |
0 |
2(2) |
| AFA |
32 (46)† |
3 (8) |
9 (7) |
| Anti-Sa |
18 (26)† |
5(14)‡ |
3 (2) |
| Anti-CCP |
38 (54)† |
5 (14) |
12 (9) |
| AKA |
26 (37)† |
1 (3) |
21 (16) |
| Anti-RA-1 |
23 (33) |
10 (28) |
49 (37) |
| Anti-RA-33 |
2 (2) |
0 |
1 (1) |
|
|
|||
|
All values represent either number of patients (%), or means ± standard deviations. *P<0.01 compared with RA patients; †P<0.01 compared with RF - RA and nonRA; ‡P<0.01 compared with nonRA. CRP, C-reactive protein; ANA, antinuclear antibodies; AFA, antifilaggrin antibody; RNP, ribonucleoprotein; CCP, cyclic citrullinated peptide; AKA, antikeratin antibody. |
|||
|
Goldbach-Mansky et al. Arthritis Res 2000 2:236 doi:10.1186/ar93 |
|||
